Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin, Diana Muñoz Sandoval, Catherine J. Reynolds, Rocio Castro Seoane, Sherine H. Kottoor, Franziska P. Pieper, Kai-Min Lin, David K. Butler, Neil Chanchlani, Rachel Nice, Desmond Chee, Claire Bewshea, Malik Janjua, Timothy J. McDonald, Shaji Sebastian, James L. Alexander, Laura Constable, James C. Lee, Charles D. Murray, Ailsa L. Hart, Peter M. Irving, Gareth-Rhys Jones, Klaartje B. Kok, Christopher A. Lamb, Charlie W. Lees, Daniel M. Altmann, Rosemary J. Boyton, James R. Goodhand, Nick Powell and Tariq Ahmad ()
Additional contact information
Simeng Lin: Royal Devon and Exeter NHS Foundation Trust
Nicholas A. Kennedy: Royal Devon and Exeter NHS Foundation Trust
Aamir Saifuddin: St Marks Hospital and Academic Institute
Diana Muñoz Sandoval: Imperial College London
Catherine J. Reynolds: Imperial College London
Rocio Castro Seoane: Imperial College London
Sherine H. Kottoor: Imperial College London
Franziska P. Pieper: Imperial College London
Kai-Min Lin: Imperial College London
David K. Butler: Imperial College London
Neil Chanchlani: Royal Devon and Exeter NHS Foundation Trust
Rachel Nice: University of Exeter
Desmond Chee: Royal Devon and Exeter NHS Foundation Trust
Claire Bewshea: University of Exeter
Malik Janjua: Royal Devon and Exeter NHS Foundation Trust
Timothy J. McDonald: Royal Devon and Exeter NHS Foundation Trust
Shaji Sebastian: Hull University Teaching Hospitals NHS Trust
James L. Alexander: Imperial College London
Laura Constable: Imperial College London
James C. Lee: Royal Free London NHS Foundation Trust
Charles D. Murray: Royal Free London NHS Foundation Trust
Ailsa L. Hart: St Marks Hospital and Academic Institute
Peter M. Irving: Guy’s and St Thomas’ NHS Foundation Trust
Gareth-Rhys Jones: Western General Hospital, NHS Lothian
Klaartje B. Kok: Royal London Hospital, Barts Health NHS Trust
Christopher A. Lamb: Newcastle upon Tyne Hospitals NHS Foundation Trust
Charlie W. Lees: Western General Hospital, NHS Lothian
Daniel M. Altmann: Imperial College London
Rosemary J. Boyton: Imperial College London
James R. Goodhand: Royal Devon and Exeter NHS Foundation Trust
Nick Powell: Imperial College London
Tariq Ahmad: Royal Devon and Exeter NHS Foundation Trust

Nature Communications, 2022, vol. 13, issue 1, 1-14

Abstract: Abstract Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity. Geometric mean [SD] anti-S RBD antibody concentrations are lower and half-lives shorter in patients treated with infliximab than vedolizumab, following two doses of BNT162b2 (566.7 U/mL [6.2] vs 4555.3 U/mL [5.4], p

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-28517-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28517-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-28517-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().